Safety of drug therapies used for weight loss and treatment of obesity

Ioannides-Demos, Lisa L.; Proietto, Joseph; Tonkin, Andrew M.; McNeil, John J.
February 2006
Drug Safety;2006, Vol. 29 Issue 4, p277
Academic Journal
journal article
Some of the medications used for weight loss in the management of obesity have been associated with unacceptable morbidity and mortality. Safety concerns have led to the withdrawal of aminorex, followed by the fenfluramines in 1997, and phenylpropanolamine (norephedrine) in 2000. Aminorex was associated with an increased prevalence of primary pulmonary hypertension (PPH), fenfluramines with an increased prevalence of PPH and valvulopathy, and phenylpropanolamine with an increased risk of haemorrhagic stroke.Several studies have investigated the safety of the fenfluramines, yet the benefit-risk profile has not been conclusively quantified. This is due to several deficiencies in the published studies, including a lack of data on the baseline prevalences of comorbid conditions in obese subjects, and potential confounders and biases in the study designs. Although several studies and systematic reviews support an increased risk of PPH and valvulopathy in patients who have taken fenfluramines, without knowledge of the background prevalence it is not possible to determine if the exposure preceded the outcome. The population at higher risk of these adverse effects includes those taking higher doses or with a longer duration of exposure to fenfluramines and those with pre-existing cardiac disease or a genetic predisposition. Patients exposed to fenfluramines continue to be monitored, with some follow-up studies indicating no overall worsening in valvulopathy over time.There are limited efficacy and safety data for amfepramone (diethylpropion) and phentermine and their approval for the management of obesity is limited to short-term use. Orlistat and sibutramine are the only currently approved medications for long-term management of obesity. Although the benefit-risk profiles of sibutramine and orlistat appear positive, sibutramine continues to be monitored because of long-term safety concerns.The safety and efficacy of currently approved drug therapies have not been evaluated in children and elderly patient populations and there is limited information in adolescents, whilst the long-term safety of current and potential new drug therapies in adults will require several years of postmarketing surveillance to fully elucidate their adverse effect profiles.


Related Articles

  • Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat. Chaput, J.-P.; St-Pierre, S.; Tremblay, A. // Mini Reviews in Medicinal Chemistry;Jan2007, Vol. 7 Issue 1, p3 

    The currently available drugs for long-term treatment of obesity are sibutramine and orlistat. They have been shown to be able to induce significant weight loss, with important co-morbidity reduction, allowing the maintenance of reduced body weight for at least 1-2 years. Cardiostimulating and...

  • Evaluation of Safety and Anti-obese Activity of a Polyherbal Formulation -- Simlim Capsule. Shah, Bijal N.; Soni, Hardik K.; Patel, Ghanshyam R.; Patel, Pooja D.; Paranjape, Archana N. // International Journal of Pharmaceutical & Phytopharmacological R; 

    Obesity is one the most common and now considered as global health problem which triggers many other metabolic disorders. In the present study, a polyherbal formulation - Simlim Capsule was evaluated for its anti-obesity activity in high fat diet (HFD) induced male Wistar albino rats. It was...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Primary care physicians can help patients lose weight.  // South African Family Practice;Oct2012, Vol. 54 Issue 5, p421 

    The article presents a brief summary of a study that identified the most effective way to help patients lose weight in the primary care setting. Adults 21 years or older with a body mass index between 30 kilograms per square meter (kg/m2) and 50 kg/m2 in Pennsylvania. Findings show that...

  • OBESITY TREATMENTS. Haslam, David // Pulse;10/31/2007, Vol. 67 Issue 39, p40 

    The author discusses several information on treatments for obesity. The author talks about the therapeutics that can be applied in alleviating corpulence. He includes the historical background for obesity treatment including mercury, arsenic, and strychnine. At the same time, he also cites the...

  • Pharmacotherapy for obesity in menopausal women. Samat, Ashish; Rahim, Asad; Barnett, Anthony // Menopause International;Jun2008, Vol. 14 Issue 2, p57 

    Weight gain, during and after the menopause is common. Contributing factors include ethnicity, reduced physical activity, reduced lean mass, reduced resting metabolic rate and treatment with certain drugs, e.g. steroids, insulin, glitazones. Excess body weight increases the risk of medical...

  • Xenical. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p809 

    An encyclopedia entry for "Xenical" is presented. It refers to a brand name of a drug pharmacologically called orlistat. The drug Xenical is commonly used for the treatment of patients who are exhibiting symptoms of mild to moderate obesity and more on those who are already on the stage of...

  • Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity. Farina, Maria; Baratta, Roberto; Nigro, Angela; Vinciguerra, Federica; Puglisi, Concetta; Schembri, Roberto; Virgilio, Clara; Vigneri, Riccardo; Frittitta, Lucia // Obesity Surgery;Apr2012, Vol. 22 Issue 4, p565 

    Background: Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes...

  • Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet–exercise intervention. Bérubé-Parent, S; Prud'homme, D; St-Pierre, S; Doucet, E; Tremblay, A // International Journal of Obesity & Related Metabolic Disorders;Aug2001, Vol. 25 Issue 8, p1144 

    OBJECTIVE: Sibutramine favors a negative energy balance and also has the potential to increase heart rate and blood pressure. We investigated if a progressive supervised sibutramine-diet-exercise clinical intervention could increase the body weight loss previously reported while minimizing the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics